GenVec, Inc.

( )
GNVC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.14%148.450.7%$817.55m
BMYBristol-Myers Squibb Co. -0.82%66.881.0%$766.87m
PFEPfizer Inc. 1.29%40.710.9%$619.15m
MRKMerck & Co., Inc. -1.26%88.520.7%$606.57m
ABBVAbbVie, Inc. -2.23%85.272.3%$577.01m
LLYEli Lilly & Co. -0.27%141.181.1%$410.25m
NVSNovartis AG -0.31%94.920.2%$122.34m
APLSApellis Pharmaceuticals, Inc. -0.42%42.290.0%$116.99m
GSKGlaxoSmithKline Plc 0.08%47.830.2%$97.55m
AZNAstraZeneca Plc -0.48%50.211.2%$92.99m
KRTXKaruna Therapeutics, Inc. -13.46%99.750.0%$72.42m
NVONovo Nordisk A/S 0.46%61.600.1%$67.09m
SNYSanofi 0.41%49.600.2%$61.96m
RETAReata Pharmaceuticals, Inc. -1.40%206.823.5%$61.74m
ENDPEndo International Plc 4.35%6.608.8%$47.74m

Company Profile

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).